Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does screening for prostate cancer identify clinically important disease?

M R Feneley1

  • 1Brady Urological Institute, Johns Hopkins Hospital, Baltimore, USA.

Annals of the Royal College of Surgeons of England
|June 12, 1999
PubMed
Summary

Digital rectal examination (DRE) and prostate-specific antigen (PSA) effectively detect early prostate cancer. PSA screening is recommended for men with a 10-year life expectancy to enable early treatment and prevent advanced disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of oncological and iatrogenic urinary incontinence in malignant disease.

Clinical oncology (Royal College of Radiologists (Great Britain))·2010
Same author

Palliation of male genital cancers.

Clinical oncology (Royal College of Radiologists (Great Britain))·2010
Same author

Surgical palliation in malignant disease.

Clinical oncology (Royal College of Radiologists (Great Britain))·2010
Same author

Pelvic exenterative surgery for palliation of malignant disease in the robotic era.

Clinical oncology (Royal College of Radiologists (Great Britain))·2010
Same author

PSA testing: an evolving relationship with prostate cancer screening.

Prostate cancer and prostatic diseases·2005
Same author

Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH.

Prostate cancer and prostatic diseases·2005

Area of Science:

  • Urology
  • Oncology
  • Diagnostic Medicine

Background:

  • Early prostate cancer detection is crucial for effective treatment and improved patient outcomes.
  • Digital rectal examination (DRE) and serum prostate-specific antigen (PSA) are established screening tools.
  • Prostate-specific antigen (PSA) can identify cancers missed by DRE, including incidental findings during transurethral resection of the prostate (TURP).

Purpose of the Study:

  • To evaluate the effectiveness of combining DRE and PSA for early prostate cancer detection in urological out-patient settings.
  • To assess the significance of PSA-detected, non-palpable prostate cancers.
  • To determine the clinical relevance of PSA-detected tumors in men with a life expectancy of at least 10 years.

Main Methods:

  • Retrospective analysis of urological out-patient data.

Related Experiment Videos

  • Combination of digital rectal examination (DRE) and serum prostate-specific antigen (PSA) testing.
  • Evaluation of pathological extent and progression of PSA-detected tumors.

    • Main Results:

    • The combination of DRE and PSA is effective for early prostate cancer detection.
    • PSA identifies cancers missed by DRE, including incidental cancers post-TURP.
    • PSA-detected, non-palpable tumors are often clinically significant and may progress if untreated.

    Conclusions:

    • Combining DRE and PSA enhances early prostate cancer detection in out-patient settings.
    • PSA screening is valuable for identifying clinically significant tumors, especially in men with a sufficient life expectancy.
    • Early detection and treatment of PSA-identified prostate cancers can prevent mortality and morbidity associated with advanced disease.